A Phase 1 interventional study of 5-MeO-DMT and Placebo in Pharmacokinetics in Healthy Adults, sponsored by Beckley Psytech Limited. Completed at 1 site in United Kingdom. Open to participants aged 25 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-10-12.
Sponsored by Beckley Psytech Limited (part of Eli Lilly and Company) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The study will evaluate safety, tolerability and PK profile of 5-MeO-DMT in healthy subjects
Beckley Psytech Limited is the lead sponsor of 6 studies on the registry; 1 is open to participants now.
First submitted before Beckley Psytech Limited became part of Eli Lilly and Company.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
* Medically healthy based on medical records and study specific assessments
Exclusion Criteria:
* Presence or history of severe adverse reaction to any drug or drug
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: 5-MeO-DMT
Other: Placebo
A single dose of 5-MeO-DMT will be administered intranasally
A single dose of placebo will be administered intranasally
Percentage of subjects with treatment emergent AEs (TEAES)
Time frame: From screening through to the follow up visit, up to 65 days
Peak plasma concentration (Cmax)
Time frame: Day 1 (dosing day) and Day 2
Time to reach Cmax (tmax)
Time frame: Day 1 (dosing day) and Day 2
Area under the plasma concentration- time curve
Time frame: Day 1 (dosing day) and Day 2
Plan to share: No — Due to the UK GDPR, individual participant data will not be shared publicly. Group data will be presented in publication after study completion
No publications or documents are linked to this record.
Ran from Sep 2021 to primary completion in Jul 2022, 9 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Methoxydimethyltryptamines